Vancomycin (** Vancocin, Firvanq (generic vancomycin is widely available) **)

Other Medications

Description

Vancomycin is an antibiotic medication. It is primarily used to treat serious bacterial infections, often those caused by bacteria resistant to other antibiotics. In the context of colorectal cancer research, vancomycin is being studied in specific clinical trials, particularly in combination with other treatments like fecal microbiota transplant (FMT) and immunotherapy drugs (like pembrolizumab or nivolumab). These trials are investigating its potential role in patients with mismatch repair deficiency (dMMR) metastatic colorectal cancer who may not respond well to standard immunotherapy. The goal is to see if vancomycin, possibly by altering the gut bacteria, can help improve the effectiveness of immunotherapy in these patients. It is important to note that vancomycin is not a standard treatment for colorectal cancer itself, but rather is being explored in research settings for specific patient populations and in combination with other therapies.

Mechanism of Action

Vancomycin works by inhibiting the growth of susceptible bacteria. It binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors, which are essential for bacterial cell wall synthesis. This action disrupts the formation of the bacterial cell wall, leading to cell death. In the context of the clinical trial (NCT04729322), vancomycin is being used alongside fecal microbiota transplant (FMT). The specific mechanism by which vancomycin might influence the response to immunotherapy in dMMR CRC patients is still under investigation, but it may relate to its effects on the gut microbiome composition, potentially enhancing the activity of immunotherapy.

Side Effects

Vancomycin Like other antibiotics Can cause side effects. Common side effects include nausea Vomiting Diarrhea And abdominal pain. More serious side effects can occur Such as kidney problems (nephrotoxicity) Hearing loss (ototoxicity) And allergic reactions. In the context of the clinical trial (NCT04729322) The specific side effect profile when used with FMT and immunotherapy is being carefully monitored. Patients participating in such trials will have their side effects closely tracked. It's crucial for patients to discuss potential side effects with their healthcare team before starting any new treatment Including investigational therapies.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04729322 med_phase_prefix2
Active, not recruiting
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
United States